Published in Proc R Soc Med on January 01, 1976
Physical hazards. Postgrad Med J (1975) 1.50
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med (1992) 5.65
Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol (1994) 3.35
Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet (1973) 3.04
Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med (1998) 3.01
Oestrogen, proestogen and liver function tests. Acta Obstet Gynecol Scand (1968) 1.78
Infections, inflammation, and the risk of coronary heart disease. Circulation (2000) 1.77
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care (1992) 1.75
Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis (1991) 1.66
Serum-digoxin concentrations during treatment with different preparations. Lancet (1971) 1.56
Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation (1999) 1.48
Ambulatory electrocardiographic recording in endurance athletes. Br Heart J (1982) 1.42
Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension (1995) 1.30
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med (1993) 1.29
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation (1995) 1.21
The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med (1994) 1.20
Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med (1994) 1.15
Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med (1981) 1.14
The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J Intern Med (1994) 1.09
HDL cholesterol and mortality in Finnish men with special reference to alcohol intake. Circulation (1994) 1.07
Oral contraceptives after liver disease. Br Med J (1971) 1.05
Movements of sodium and potassium ions and their tracers in propranolol-treated red cells and diaphragm muscle. Acta Physiol Scand Suppl (1970) 1.01
Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J (1994) 1.00
Minimal doses of digoxin: a new marker for compliance to medication. Eur Heart J (1987) 1.00
Endothelium-dependent and -independent effects of exogenous ATP, adenosine, GTP and guanosine on vascular tone and cyclic nucleotide accumulation of rat mesenteric artery. Br J Pharmacol (1992) 0.99
Ear-lobe crease and coronary atherosclerosis. Lancet (1980) 0.98
Urinary excretion of porphyrin precursors and coproporphyrin in healthy females on oral contraceptives. Br Med J (1966) 0.97
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation (1995) 0.94
Electrocardiographic abnormalities and some laboratory findings in patients with subarachnoid haemorrhage. Br Heart J (1972) 0.92
Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis (1994) 0.92
How to define coronary heart disease in register-based follow-up studies: experience from the Helsinki Heart Study. Ann Med (1997) 0.91
Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb (1993) 0.91
Diurnal variation of plasma angiotensin II in man. Scand J Clin Lab Invest (1973) 0.91
Maintenance of potassium balance during diuretic therapy. Acta Med Scand (1979) 0.90
Tablet disintegration: possible link with biological availability of digoxin. Lancet (1972) 0.90
Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J (1987) 0.90
Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. Br J Haematol (1998) 0.89
Exogenous GTP enhances the effects of sodium nitrite on cyclic GMP accumulation, vascular smooth muscle relaxation and platelet aggregation. Pharmacol Toxicol (1991) 0.89
Ambulatory electrocardiographic findings in young athletes between 14 and 16 years of age. Eur Heart J (1984) 0.88
Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost (1996) 0.88
Ion movements in red cells treated with propranolol. Acta Physiol Scand (1969) 0.86
Human serum and myocardium digoxin. Clin Pharmacol Ther (1976) 0.85
Guar gum and gemfibrozil--an effective combination in the treatment of hypercholesterolaemia. Atherosclerosis (1989) 0.85
Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease. Hum Genet (1991) 0.85
Interaction of thallous ions with the cation transport mechanism in erythrocytes. Biochim Biophys Acta (1973) 0.85
Composition of pericardial fluid in cholesterol pericarditis. Acta Med Scand (1972) 0.85
Medication compliance and serum lipid changes in the Helsinki Heart Study. Br J Clin Pharmacol (1991) 0.84
Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism (1991) 0.84
Seasonal variation in high density lipoprotein cholesterol. Atherosclerosis (1993) 0.84
Angiotensin II plasma levels in hypertensive patients. Acta Med Scand (1972) 0.84
Non-equivalence of digoxin tablets. Ann Clin Res (1974) 0.84
Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. Acta Med Scand (1986) 0.84
Alcohol and coronary heart disease: the roles of HDL-cholesterol and smoking. J Intern Med (1997) 0.83
Investigations on the effect of an oral contraceptive and its components on liver function, serum proteins, copper, coeruloplasmin and gamma-glutamyl peptidase in postmenopausal women. Scand J Gastroenterol (1968) 0.83
QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. Heart (1997) 0.83
Clinical results with gemfibrozil and background to the Helsinki Heart Study. Am J Cardiol (1983) 0.83
Fluorescence angiography of the fundus vessels in aortic coarctation. Br Heart J (1970) 0.82
Herpes simplex virus encephalitis: new diagnostic and clinical features and results of therapy. Arch Neurol (1980) 0.82
Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men. Atherosclerosis (2001) 0.82
Tumefactive liver infiltration in amyloidosis. Ann Clin Res (1982) 0.82
Coronary ostium outside the aortic sinus. A factor in the aetiology of ischaemic heart disease? Adv Cardiol (1970) 0.82
Effect of diazepam on endothelial permeability, plasma lipids and lipoproteins in cholesterol fed rabbits. Acta Med Scand Suppl (1982) 0.81
Letter: impaired colour vision in diagnosis of digitalis intoxication. Br Med J (1974) 0.81
Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine. Eur J Clin Pharmacol (1989) 0.81
Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J (2001) 0.81
Compliance with medication in the Helsinki Heart Study. Eur J Clin Pharmacol (1992) 0.80
Correlation of digoxin-tablet dissolution-rate with biological availability. Br J Clin Pharmacol (1977) 0.80
Effects of single doses of quinapril and atenolol on autonomic nervous function and exercise capacity in healthy volunteers. Eur J Clin Pharmacol (1990) 0.80
Serum-digoxin concentrations with a new digoxin derivative, beta-methyl-digoxin. Ann Clin Res (1973) 0.80
Effect of activated charcoal on hypercholesterolaemia. Lancet (1986) 0.80
Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women. Maturitas (1987) 0.79
Lack of serum cholesterol-lowering effect of skimmed milk and butter milk under controlled conditions. Atherosclerosis (1981) 0.79
Ambulatory electrocardiographic recording in mild or moderate myotonic dystrophy and myotonia congenita (Thomsen's disease). J Neurol Sci (1983) 0.79
The Helsinki Heart Study: central findings and clinical implications. Ann Med (1991) 0.79
Factors affecting the relative magnitudes of the ouabain-sensitive and the ouabain-insensitive fluxes of thallium ion in erythrocytes. Biochim Biophys Acta (1978) 0.79
Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin. J Steroid Biochem Mol Biol (1993) 0.79
Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. Acta Med Scand Suppl (1982) 0.79
Modification of nitrovasodilator effects on vascular smooth muscle by exogenous GTP and guanosine. J Cardiovasc Pharmacol (1991) 0.79
Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Med Scand Suppl (1982) 0.79
High-density lipoprotein cholesterol elevation with gemfibrozil: effects of baseline level and modifying factors. Clin Pharmacol Ther (1993) 0.78
Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress. Clin Pharmacol Ther (1988) 0.78
Acute encephalitis. A survey of epidemiological, clinical and microbiological features covering a twelve-year period. Acta Med Scand (1981) 0.78
Cigarette smoking alters sympathoadrenal regulation by decreasing the density of beta 2-adrenoceptors. A study of monitored smoking cessation. J Cardiovasc Pharmacol (1991) 0.78
Leukocytes as a coronary risk factor in a dyslipidemic male population. Am Heart J (1992) 0.77
Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Med Scand (1981) 0.77
Treatment of hypertension in the elderly with labetalol. Acta Med Scand Suppl (1982) 0.77
The effect of alprenolol in elderly patients with raised blood pressure. Acta Med Scand Suppl (1974) 0.77
DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment. Clin Pharmacol Ther (1991) 0.77
Syncope and Q-T prolongation without deafness: the Romano-Ward syndrome. Am Heart J (1970) 0.77
A long-term trial of gemfibrozil in the treatment of hyperlipidaemias. Proc R Soc Med (1976) 0.77
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial. Control Clin Trials (1997) 0.77
Sleep and cardiac rhythm in healthy men. Ann Med (1991) 0.77
The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med (1995) 0.77
Influence of a psyllium-based fibre preparation on faecal and serum parameters. Acta Med Scand Suppl (1982) 0.77
Effects of indomethacin on hormonal and blood pressure responses to captopril in spontaneously hypertensive rats. Pharmacol Toxicol (1987) 0.77
Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia. Acta Med Scand Suppl (1982) 0.76